Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bandwidth Inc (BAND) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Bandwidth IncTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Bandwidth Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Bandwidth Inc trades at $51.42 (market cap $1.66B), while Ginkgo Bioworks Holdings Inc trades at $7.25 (market cap $505.73M). The key difference: Bandwidth Inc is far larger — about 3.3× Ginkgo Bioworks Holdings Inc's market cap, and Bandwidth Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.

BANDDNA
Market Cap
$1.66B$505.73M
Sector
TechnologyHealth
52-Week High
$78.44$16.14
52-Week Low
$12.82$5.48
Enterprise Value
$2.04B$607.68M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bandwidth Inc

Bandwidth (BAND) trades at $51.97, down 1.4% over 24 hours, with a bullish technical outlook supported by moving averages despite overbought RSI signals. The company reported strong Q2 2026 results, beating EPS estimates with $0.37 versus $0.3652 expected, and raised its full-year outlook on AI-driven demand growth. Revenue climbed 22% year-over-year to $220 million, though net income margins remain thin at 0.27% for 2026.

The stock offers upside to the $75.25 analyst consensus target, fueled by AI adoption and enterprise wins, but risks include high valuation multiples like a 34.08 EV/EBITDA and competitive pressures in cloud communications. Execution on profitability improvements will be critical for sustaining gains.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.

DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.

Returns comparison

Trailing returns across standard periods

About Bandwidth Inc

Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.

Read more on BAND

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA